Company overview
InDevR provides multiplexed analytical solutions via its VaxArray platform for vaccine development, optimization, and quality control, supporting mRNA, polysaccharide, conjugate, and viral vector vaccines. The platform offers validated off-the-shelf and custom kits, such as 5'CapQ for rapid mRNA capping efficiency assessment in under two hours and pneumococcal assays for 23 serotypes in a single test. Acquired by SSI Diagnostica Group, InDevR also delivers expert services to streamline workflows and enhance assay sensitivity for pharmaceutical manufacturers.
Indevr is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include vaccine testing, vaxarray, mrna vaccines, pneumococcal assay, analytical solutions.
Products and technologies associated with Indevr include Assay — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.indevr.com
- Markets served
- United States & Americas
- Keywords
- vaccine testing, vaxarray, mrna vaccines, pneumococcal assay, analytical solutions
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What is InDevR's VaxArray platform?
- VaxArray is an automated, microarray-based multiplexed platform offering validated and custom kits to simplify vaccine workflows, enabling simultaneous quantification of multiple analytes like serotypes or mRNA quality attributes in a single test.
- What vaccine types does InDevR support?
- InDevR supports mRNA, polysaccharide, conjugate, pneumococcal, and viral vector vaccines with specialized assays for in-process control, potency, stability, and quality assessment.
- Where is InDevR located and how to contact?
- InDevR is based in Boulder, Colorado, USA at 6035 Longbow Dr., Suite 102. Contact [email protected] or +1 303-402-9100 for inquiries.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
